Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First ...

Retrieved on: 2023-09-11 13:58:46

Tags for this article:

Breakthrough therapy

Orphan drugs

Antineoplastic drugs

Lung cancer

Cancer treatments

Trastuzumab deruxtecan

Durvalumab

Treatment of lung cancer

Daiichi Sankyo

Non-small-cell lung cancer

Click the tags to see associated articles and topics

Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First .... View article details on HISWAI: https://pipelinereview.com/index.php/2023091184182/Antibodies/Datopotamab-Deruxtecan-Plus-Durvalumab-Showed-Promising-Clinical-Activity-in-the-First-Line-Advanced-Non-Small-Cell-Lung-Cancer-Setting-in-TROPION-Lung04-Phase-1b-Trial.html

Excerpt

Details: Category: Antibodies: Published on Monday, 11 September 2023 09:53 ... is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, ...

Article found on: pipelinereview.com

View Original Article